Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xenetix CT Perfusion in Hepatocellular Carcinoma
NCT01639703Phase 4Completed
- Sponsor
- Guerbet
- Start
- Apr 2012
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 4, open-label trial of iobitridol in hepatocellular carcinoma (HCC), sponsored by Guerbet. Primary endpoints: Blood Volume at 1 week, Blood Flow at 1 week and 1 more. Started Apr 2012; status: completed.
02
Drugs
iobitridol
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01639703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01639703.